Analytical Data
-
Gene name
APOBEC3G
- Application
-
Alternative Names
APOBEC3G；DNA dC->dU-editing enzyme APOBEC-3G
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9HC16
-
Expression Region
1-384aa
-
AA Sequence
MKPHFRNTVERMYRDTFSYNFYNRPILSRRNTVWLCYEVKTKGPSRPPLDAKIFRGQVYSELKYHPEMRFFHWFSKWRKLHRDQEYEVTWYISWSPCTKCTRDMATFLAEDPKVTLTIFVARLYYFWDPDYQEALRSLCQKRDGPRATMKIMNYDEFQHCWSKFVYSQRELFEPWNNLPKYYILLHIMLGEILRHSMDPPTFTFNFNNEPWVRGRHETYLCYEVERMHNDTWVLLNQRRGFLCNQAPHKHGFLEGRHAELCFLDVIPFWKLDLDQDYRVTCFTSWSPCFSCAQEMAKFISKNKHVSLCIFTARIYDDQGRCQEGLRTLAEAGAKISIMTYSEFKHCWDTFVDHQGCPFQPWDGLDEHSQDLSGRLRAILQNQEN
-
Molecular Weight
62.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
APOBEC3G is a member of the APOBEC family of proteins, which play a crucial role in the innate immune response against viral infections, particularly in the context of retroviruses such as HIV. This cytidine deaminase is known for its ability to edit viral genomes, causing hypermutations that can inhibit viral replication and promote the degradation of reverse-transcribed viral DNA. Research on APOBEC3G has gained significant attention due to its potential as a therapeutic target for controlling HIV infection and its role in shaping viral evolution. Despite its protective functions, APOBEC3G has also been implicated in cancer pathogenesis, where it can contribute to the mutagenesis of host cells. Understanding the mechanisms of action, regulation, and the balance between its antiviral and oncogenic roles is vital. The recombinant expression of APOBEC3G in cellular models has facilitated the study of its enzymatic activity, interaction with viral components, and its influence on the host's immune response. Current research endeavors aim to elucidate the molecular pathways involved in APOBEC3G’s activities, explore its potential as a biotherapeutic agent, and understand the implications of its dysregulation in viral infections and cancer. This multifaceted approach underscores the significance of APOBEC3G research in both virology and oncology, highlighting its promise as a target for innovative therapeutic strategies.
